PHGUF (PHGUF) Stock Price & Analysis
PHGUF (PHGUF) rose 0.00% to USD 1.1 as of September 9, 2026 at 19:57 UTC, according to Nexqual real-time market data.
PHGUF last closed at USD 1.1; the session ranged USD 1.18–1.2 on volume of 500 shares. Market capitalization is $778.56M, with a 52-week range of USD 1.1–2.17 (PNK). Source: Nexqual, September 9, 2026 at 19:57 UTC.
Key Statistics (as of September 9, 2026 at 19:57 UTC)
| Price | USD 1.1 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.1 |
| Open | USD 1.2 |
| Day Range | USD 1.18 – 1.2 |
| 52-Week Range | USD 1.1 – 2.17 |
| Volume | 500 shares |
| Market Cap | $778.56M |
| Exchange | PNK |
Technical Analysis (PHGUF)
Nexqual's technical model rates PHGUF "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 19:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 1.22) |
| MACD | -0.04 (negative) |
Analyst Ratings (PHGUF)
Wall Street analysts rate PHGUF "None", per Nexqual as of September 9, 2026 at 19:57 UTC.
| Consensus Rating | None |
|---|
Earnings (PHGUF)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $104.07M |
Source: Nexqual, September 9, 2026 at 19:57 UTC.
Financials & Fundamentals (PHGUF)
| Total Revenue | $366.48M |
|---|---|
| Revenue Growth (YoY) | -3.20% |
| Gross Margin | +86.52% |
| Operating Margin | +1.46% |
| Profit Margin | +2.54% |
| ROE | +3.65% |
| Debt / Equity | 41.89 |
| Current Ratio | 3.01 |
| Total Cash | $158.28M |
| Total Debt | $113.30M |
| Free Cash Flow | $37.69M |
Source: Nexqual, September 9, 2026 at 19:57 UTC.
Ownership (PHGUF)
| Insider Ownership | +1.95% |
|---|---|
| Institutional Ownership | +22.97% |
| Shares Outstanding | 707.78M |
| Float | 696.57M |
Source: Nexqual, September 9, 2026 at 19:57 UTC.
Leadership (PHGUF)
PHGUF is led by Fabrice Chouraqui M.B.A., Ph.D., Pharm.D., CEO & Executive Director, per Nexqual as of September 9, 2026 at 19:57 UTC.
| CEO & Executive Director | Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. |
|---|---|
| Chief Financial Officer | Kenneth Lynard EMBA, M.Sc. (age 57) |
| Medical Director | Magnus Hansson (age 49) |
Major Backers & Investors (PHGUF)
Notable institutional backers of PHGUF include DFA INVESTMENT TRUST CO-The Continental Small Company Series, Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund, SEI INSTITUTIONAL INVESTMENTS TRUST-SIIT World Equity EX-US Fund, according to Nexqual as of September 9, 2026 at 19:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Continental Small Company Series | 0.7% |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 0.26% |
| SEI INSTITUTIONAL INVESTMENTS TRUST-SIIT World Equity EX-US Fund | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.89% |
| Dimensional Fund Advisors | 0.17% |
Source: Nexqual, September 9, 2026 at 19:57 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GGIFF | Garibaldi Resources Corp. | USD 0.05 | ▲ 0% |
| PTCHF | PureTech Health PLC | USD 1.65 | ▲ 5.5% |
| IGGGF | IGG INC | USD 0.43 | ▲ 0% |
| DMPZF | Domino's Pizza Australia New Ze | USD 2.65 | ▲ 0% |
| SBMFF | SINO BIOPHARMACEUTICAL | USD 0.74 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 19:57 UTC. This page is informational and not investment advice.